676 Results

People

  1. Robson
    Robson
  2. Offit
    Offit
  3. Stadler
    Stadler
  4. Joseph
    Joseph
  5. Mandelker
    Mandelker
  6. Berger
    Berger
  7. Solit
    Solit
  8. Hudis
    Hudis
  9. Kauff
    Kauff
  10. Kemel
    Kemel

Groups

  1. Breast Medicine Service (676)
  2. Department of Medicine (676)
  3. Population Sciences Research Program (676)
  4. Solid Tumor Oncology Division (676)
  5. Survivorship Research (676)
  6. GSK Faculty (376)
  7. Clinical Genetics Service (297)
  8. Surgery (188)
  9. Department of Pathology and Laboratory Medicine (187)
  10. Epidemiology and Biostatistics (185)
  1. "Mark Robson"
Formats
  1. Journal Article (382)
  2. Meeting Abstract (259)
  3. Review (10)
  4. Book Section (7)
  5. Editorial (6)
  6. Guidelines (6)
  7. Miscellaneous (4)
  8. Correspondence (1)
  9. Research Letter (1)
Groups
  1. Breast Medicine Service (676)
  2. Department of Medicine (676)
  3. Population Sciences Research Program (676)
  4. Solid Tumor Oncology Division (676)
  5. Survivorship Research (676)
  6. GSK Faculty (376)

More Groups

People
  1. Mark Robson (676)
  2. Kenneth Offit (280)
  3. Zsofia Stadler (116)
  4. Larry Norton (89)
  5. Vijai Joseph (79)
  6. Diana Mandelker (74)

More People

Years
  1. 2025 (2)
  2. 2024 (32)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (46)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (163)
  2. Cancer Research (50)
  3. Breast Cancer Research and Treatment (33)
  4. JNCI: Journal of the National Cancer Institute (20)
  5. Annals of Oncology (18)
  6. Clinical Cancer Research (17)

More Publications

Publishers
  1. American Society of Clinical Oncology (185)
  2. American Association for Cancer Research (82)
  3. Springer (66)
  4. Nature Publishing Group (60)
  5. Elsevier Inc. (50)
  6. Oxford University Press (42)

More Publishers

Results (676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model
    Meeting Abstract

    Gallagher, S.; Hughes, E.; Kurian, A. W.; Domchek, S. M.; Garber, J. E.; Probst, B.; Morris, B.; Tshiaba, P.; Rosenthal, E. T.; Roa, B.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Incidence of brain metastases in patients receiving neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in HER2-positive early breast cancer (BC)
    Meeting Abstract

    Ferraro, E.; Barrio, A. V.; Patil, S.; Robson, M. E.; Dang, C. T.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Prospective agnostic germline testing in pediatric cancer patients
    Meeting Abstract

    Fiala, E.; Kennedy, J.; Kemel, Y.; Mauguen, A.; Mandelker, D.; Zehir, A.; Birsoy, O.; Bouvier, N.; Maio, A.; Latham, A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT)
    Meeting Abstract

    Domchek, S. M.; Brower, J.; Symecko, H.; Marcell, V.; Walsh, M. F.; Hamilton, J. G.; Couch, F.; Offit, K.; Garber, J. E.; Robson, M. E.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The optimal living and wellness program: Piloting a novel survivorship care model
    Meeting Abstract

    Corcoran, S.; Russell, J.; Smith, A.; Kelly, B.; Clayton, J.; Stein, B.; Keenan, K.; Robson, M. E.; Iyengar, N. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Evaluating the association between clonal hematopoiesis and germline pathogenic and likely pathogenic variants in cancer predisposition genes
    Meeting Abstract

    Comen, E. A.; Razavi, P.; Patel, P. B.; Martin, A.; Seshan, V. E.; Mandelker, D.; Ptashkin, R.; Kemel, Y.; Stadler, Z. K.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Characterization of patients with multiple primary tumors
    Meeting Abstract

    Cadoo, K. A.; Mukherjee, S.; Khurram, A.; Kemel, Y.; Tkachuk, K.; Liu, Y. L.; Carlo, M. I.; Walsh, M. F.; Latham, A.; Dubard-Gault, M. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Disparities in work status after treatment for breast cancer: A controlled, longitudinal study
    Meeting Abstract

    Blinder, V. S.; Patil, S.; Eberle, C.; Jung, G.; Kampel, L. J.; Hwang, C.; Bao, T.; Robson, M. E.; Malik, M.; Gany, F.
    Cancer Epidemiology Biomarkers and Prevention (2020)

    Fulltext@MSK | Save
  • A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab plus chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009
    Meeting Abstract

    Rugo, H. S.; Llombart Cussac, A.; AndreĢ, F.; Robson, M.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Seok Ahn, J.; Nanda, R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma
    Journal Article

    Hoda, R. S.; Brogi, E.; Dos Anjos, C. H.; Grabenstetter, A.; Ventura, K.; Patil, S.; Selenica, P.; Weigelt, B.; Reis-Filho, J. S.; Traina, T.; more...
    Modern Pathology (2020)

    Fulltext@MSK | Save